Anti-IgE monoclonal antibodies as potential treatment in COVID-19

References

• Hanaei S, Rezaei N. COVID-19: Developing from an outbreak to a pandemic. Arch Med Res. 2020;51(6):582–584.
   PubMed Web of Science ®Google Scholar
• Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review. Life Sci. 2020;255:117839.
   PubMed Web of Science ®Google Scholar
• Xiong T-Y, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798–1800.
   PubMed Web of Science ®Google Scholar
• Chan Sun M, Lan Cheong Wah CB. Lessons to be learnt from the COVID-19 public health response in Mauritius. Public Health Pract. 2020;1:100023.
   Google Scholar
• Vally Z. Public perceptions, anxiety, and the perceived efficacy of health-protective behaviours to mitigate the spread of the SARS-Cov-2/COVID-19 pandemic. Public Health. 2020;187:67–73.
   PubMed Web of Science ®Google Scholar
• Silva PCL, Batista PVC, Lima HS, et al. COVID-ABS: An agent-based model of COVID-19 epidemic to simulate health and economic effects of social distancing interventions. Chaos, Solitons Fractals. 2020;139:110088.
   PubMed Web of Science ®Google Scholar
• Guan Y, Deng H, Zhou X. Understanding the impact of the COVID-19 pandemic on career development: Insights from cultural psychology. J Vocat Behav. 2020;119:103438.
   PubMed Web of Science ®Google Scholar
• Thakur V, Jain A. COVID 2019-suicides: A global psychological pandemic. Brain Behav Immun. 2020;88:952–953.
   PubMed Web of Science ®Google Scholar
• Elbay RY, Kurtulmuş A, Arpacıoğlu S, et al. Depression, anxiety, stress levels of physicians and associated factors in Covid-19 pandemics. Psychiatry Res. 2020;290:113130.
   PubMed Web of Science ®Google Scholar
• Bendjelid K, Giraud R, Von Düring S. Treating hypoxemic COVID-19 “ARDS” patients with almitrine: The earlier the better? Anaesthesia, Crit Care Pain Med. 2020;39(4):451–452.
   PubMed Web of Science ®Google Scholar
• Dong X, Cao Y, Lu X, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699–1709.
   PubMed Web of Science ®Google Scholar
• Momtazmanesh S, Ochs HD, Uddin LQ, et al. All together to Fight COVID-19. The Am J Trop Med Hygiene 2020;102(6):1181–1183.
   PubMed Web of Science ®Google Scholar
• Saghazadeh A, Rezaei N. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol. 2020;84:106560.
   PubMed Web of Science ®Google Scholar
• Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–98.
   PubMed Web of Science ®Google Scholar
• Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus–a perspective. Expert Rev Clin Immunol. 2020;16(5):465–466.
   PubMed Web of Science ®Google Scholar
• Tang T, Bidon M, Jaimes JA, et al. Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. Antiviral Res. 2020; 178:104792.
   PubMed Web of Science ®Google Scholar
• Yip T-F, Selim ASM, Lian I, et al. Advancements in host-based interventions for influenza treatment. Front Immunol. 2018;9:1547.
   PubMed Web of Science ®Google Scholar
• Catanzaro M, Fagiani F, Racchi M, et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Sig Transduct Target Ther. 2020;5(1):1–10.
   PubMed Web of Science ®Google Scholar
• Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infect Public Health. 2020;13(11):1619–1629.
   PubMed Web of Science ®Google Scholar
• Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci. 2020;256:117900.
   PubMed Web of Science ®Google Scholar
• Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy. 2020;75(7):1564–1581.
   PubMed Web of Science ®Google Scholar
• Taboada M, Caruezo V, Naveira A, et al. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease. J Clin Anesth. 2020;66:109926.
   PubMed Web of Science ®Google Scholar
• Abdin SM, Elgendy SM, Alyammahi SK, et al. Tackling the cytokine storm in COVID-19, challenges, and hopes. Life Sci. 2020; 257:118054.
   PubMed Web of Science ®Google Scholar
• Song YG, Shin H-S. COVID-19, a clinical syndrome manifesting as hypersensitivity pneumonitis. Infect Chemother. 2020;52(1):110–112.
   PubMed Web of Science ®Google Scholar
• Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020; 217:108487.
   PubMed Web of Science ®Google Scholar
• Martorano LM, Grayson MH. Respiratory viral infections and atopic development: From possible mechanisms to advances in treatment. Eur J Immunol. 2018;48(3):407–414.
   PubMed Web of Science ®Google Scholar
• Karamloo F, König R. SARS‐CoV‐2 immunogenicity at the crossroads. Allergy. 2020;75(7):1822–1824.
   PubMed Web of Science ®Google Scholar
• Mattos-Silva P, Felix NS, Silva PL, et al. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir Physiol Neurobiol. 2020;280:103492.
   PubMed Web of Science ®Google Scholar
• Yang J-W, Yang L, Luo R-G, et al. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin Microbiol Infect. 2020;26(9):1171–1177.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology E-book. Elsevier Health Sci. 2014:417–434.
   Google Scholar
• Klimek L, Jutel M, Akdis C, et al. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement. Allergy. 2020;75(7):1546–1554.
   Web of Science ®Google Scholar
• Smith-Norowitz TA, Wong D, Kusonruksa M, et al. Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. Int J Med Sci. 2011;8(3):239–244.
   PubMed Web of Science ®Google Scholar
• Edwards MR, Strong K, Cameron A, et al. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017;140(4):909–920.
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91–100. e3.
   PubMed Web of Science ®Google Scholar
• Dakhama A, Park J-W, Taube C, et al. The role of virus-specific immunoglobulin E in airway hyperresponsiveness. Am J Respir Crit Care Med. 2004;170(9):952–959.
   PubMed Web of Science ®Google Scholar
• Khan SH, Park SS, Sirajuddin IA, et al. Respiratory virus and asthma: the role of immunoglobulin E. Clin Ther. 2008;30:1017–1024.
   PubMed Web of Science ®Google Scholar
• Smith-Norowitz TA, Kusonruksa M, Wong D, et al. Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in serum of children and adults following influenza A vaccination with subsequent H1N1 infection: a case study. J Inflammat Res. 2012;5:111.
   PubMedGoogle Scholar
• Jacofsky D, Jacofsky EM, Jacofsky M. Understanding antibody testing for covid-19. J Arthroplasty. 2020;35(7):S74–S81.
   PubMed Web of Science ®Google Scholar
• Bønnelykke K, Vissing NH, Sevelsted A, et al. Association between respiratory infections in early life and later asthma is independent of virus type. J Allergy Clin Immunol. 2015;136(1):81–86. e4.
   PubMed Web of Science ®Google Scholar
• Oliver BG, Robinson P, Peters M, et al. Viral infections and asthma: an inflammatory interface? Eur Respiratory Soc. 2014;44(6):1666–1681.
   PubMed Web of Science ®Google Scholar
• Zhang J-j, Dong X, Cao Y-y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan. China. Allergy. 2020;75(7):1730–1741.
   PubMed Web of Science ®Google Scholar
• Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020;75(10):2703–2704.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic. Clinic Rev Allerg Immunol. 2020;59(1):78–88.
   PubMed Web of Science ®Google Scholar
• Jesenak M, Banovcin P, Diamant Z. COVID‐19, chronic inflammatory respiratory diseases and eosinophils–Observationsfrom reported clinical case series. Allergy. 2020;75(7):1819–1822.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang Y, Yang X, et al. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. Allergy. 2021;76(2):562–564.
   PubMed Web of Science ®Google Scholar
• Johnston SL. Asthma and COVID‐19: is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543–1545.
   PubMed Web of Science ®Google Scholar
• Doorley LA, LeMessurier KS, Iverson AR, et al. Humoral immune responses during asthma and influenza co-morbidity in mice. Immunobiology. 2017;222(12):1064–1073.
   PubMed Web of Science ®Google Scholar
• Bergerson JR, Freeman AF. An update on syndromes with a hyper-IgE phenotype. Immunol Allergy Clin. 2019;39(1):49–61.
   PubMed Web of Science ®Google Scholar
• Rouleau I, De Serres G, Drolet JP, et al. Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. J Allergy Clin Immunol. 2012;130(6):1423–1426.
   PubMed Web of Science ®Google Scholar
• Nagao M, Fujisawa T. Inactivated influenza vaccine induces IgE antibody to the vaccine in preschool children. J Allergy Clin Immunol. 2019;143(2):AB228.
   Web of Science ®Google Scholar
• Carli G, Cecchi L, Stebbing J, et al. Is asthma protective against COVID‐19. Allergy. 2021;76(3):866–868.
   PubMed Web of Science ®Google Scholar
• Theoharides TC. COVID‐19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors (Oxford, England). 2020;46(3):306–308.
   PubMed Web of Science ®Google Scholar
• Kawakami T, Blank U. From IgE to omalizumab. JI. 2016;197(11):4187–4192.
   Google Scholar
• Rowe RK, Pyle DM, Tomlinson AR, et al. IgE cross-linking impairs monocyte antiviral responses and inhibits influenza-driven TH1 differentiation. J Allergy Clin Immunol. 2017;140(1):294–298. e8.
   PubMed Web of Science ®Google Scholar
• Jartti T, Bønnelykke K, Elenius V, et al. Role of viruses in asthma. Semin Immunopathol. 2020;42(1):61–74.
   PubMed Web of Science ®Google Scholar
• Jartti T, Smits HH, Bønnelykke K, EAACI Task Force on Clinical Practice Recommendations on Preschool Wheeze, et al. Bronchiolitis needs a revisit: distinguishing between virus entities and their treatments. Allergy. 2019;74(1):40–52.
   PubMed Web of Science ®Google Scholar
• Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196(8):985–992.
   PubMed Web of Science ®Google Scholar
• Matucci A, Vultaggio A, Maggi E, et al. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Respir Res. 2018;19(1):113.
   PubMedGoogle Scholar
• Lommatzsch M, Stoll P, Virchow JC. COVID‐19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020;75(10):2705–2708.
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Hentzien M, Pascard M, et al. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study. Int J Antimicrob Agents. 2020;56(2):106077.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Akdis C, Jutel M, the ARIA‐MASK Study Group, et al. Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement. Allergy. 2020;75(10):2440–2444.
   Web of Science ®Google Scholar
• Lin RY, Joshi S. Pulse corticosteroids as an omalizumab enabling IgE reduction modality in an asthmatic without allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2015;135(2):AB2.
   Web of Science ®Google Scholar
• Gelincik A, Brockow K, Çelik GE, et al. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19. Allergy. 2020;75(11):2775–2793.
   PubMed Web of Science ®Google Scholar
• Pashaei M, Rezaei N. Immunotherapy for SARS-CoV-2: Potential Opportunities. Taylor and Francis. 2020;20(10):1111–1116.
   Google Scholar
• Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biologic therapies: What we need to know. World Allergy Organ J. 2020;13(5):100126.
   PubMed Web of Science ®Google Scholar
• Abdelmaksoud A, Goldust M, Vestita M. Omalizumab and COVID19 Treatment: Could It Help? Dermatologic Ther. 2020;33(4):e13792.
   Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar